Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction.

Anastasia Paulmann, Matthew D Cox, Tom Boewer, Hannah M Somers, Heath Fuqua, Ryan P Seaman, Joel H Graber, Anchal Mahajan, Cory P Johnson, Laura L Beverly-Staggs, Sonia Sandhi, Heiko Schenk, Hermann Haller

Mount Desert Island Biological Laboratory (MDIBL), Bar Harbor, Maine, USA; Division of Nephrology and Hypertension, Hannover Medical School (MHH), Hannover, Germany. Electronic address: [email protected] Desert Island Biological Laboratory (MDIBL), Bar Harbor, Maine, USA; Division of Nephrology and Hypertension, Hannover Medical School (MHH), Hannover, Germany. Electronic address: [email protected]. · pubmed

Paper

Abstract

Aging is associated with progressive loss of kidney function and vascular structure, with and without chronic kidney disease. However, the mechanisms driving kidney vascular aging and potential therapeutic interventions remain poorly understood.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Sodium-glucose co-transporter 2 inhibition can improve kidney microvascular rarefaction associated with aging. This research addresses mechanisms of kidney vascular aging, which is a critical aspect of age-related decline in organ function.

Author of this paper? Send a correction.